医学
贝伐单抗
卡铂
紫杉醇
肿瘤科
卵巢癌
内科学
阶段(地层学)
妇科
化疗
癌症
生物
古生物学
顺铂
作者
G. Freyer,Andrew Martin,F. Raspagliesi,J. Peron,Els Van Nieuwenhuysen,K. Hasegawa,Min Kyung Lim,I.L. Ray-Coquard
标识
DOI:10.1016/j.annonc.2022.07.1871
摘要
A standard therapy for advanced high grade ovarian carcinoma (AHGOC) is an upfront complete surgery followed by adjuvant platinum-taxane chemotherapy adding maintenance targeted therapies. The most common maintenance strategies include bevacizumab and PARP inhibitors. Following the results of the PRIMA (Gonzales Martin, et al NEJM 2019) and PAOLA-1 (Ray-Coquard, et al NEJM 2019) studies, the question of the most efficient maintenance therapy for FIGO stage III patients remains uncertain considering PARPi alone or in combination with bev.
科研通智能强力驱动
Strongly Powered by AbleSci AI